EDITORIAL COMMENTS ON THE ARTICLE OF M.N. MAMEDOV AND M.V. STROEVA “WHAT CAN WE EXPECT USING ACE INHIBITOR RAMIPRIL IN PERSONS WITH HIGH CARDIOVASCULAR RISK AND EARLY DISORDERS OF CARBOHYDRATE METABOLISM? LESSONS OF DREAM TRIAL”
References
1. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.
2. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096- 105.
3. Toumilechto J, Lindstr m J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
4. ESC/EASD guidelines on diabetes, pre-diabetes and cardiovascular diseases. Eur Heart J 2007;28:88-136.
Review
For citations:
Редакционная с. EDITORIAL COMMENTS ON THE ARTICLE OF M.N. MAMEDOV AND M.V. STROEVA “WHAT CAN WE EXPECT USING ACE INHIBITOR RAMIPRIL IN PERSONS WITH HIGH CARDIOVASCULAR RISK AND EARLY DISORDERS OF CARBOHYDRATE METABOLISM? LESSONS OF DREAM TRIAL”. Rational Pharmacotherapy in Cardiology. 2008;4(1):91. (In Russ.)
Views:
442
Email this article 